Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner.

OATP1B1 and OATP1B3 mediate hepatic uptake of many drugs (e.g., statins) and can mediate transporter-mediated drug-drug-interactions (DDIs). Bortezomib is the first-in-class proteasome inhibitor drug approved by the U. S. Food and Drug Administration for the treatment of multiple myeloma. The potent...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Khondoker Alam, Taleah Farasyn, Alexandra Crowe, Kai Ding, Wei Yue
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science (PLoS) 2017-01-01
Серии:PLoS ONE
Online-ссылка:http://europepmc.org/articles/PMC5673231?pdf=render
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы